Can a quicker dose ramp-up of venetoclax be safe for CLL patients?
NCT ID NCT04843904
First seen Jan 10, 2026 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This study is testing whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely increase their dose of venetoclax faster than the usual 5-week schedule. The main goal is to see which risk groups for tumor lysis syndrome can tolerate a daily dose increase. About 40 participants with newly diagnosed or returning CLL/SLL will take part, and some may also receive other drugs like obinutuzumab or rituximab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.